Danaher Co. (NYSE:DHR) Shares Bought by IFM Investors Pty Ltd

Posted by MarketBeat News on Aug 1st, 2022

IFM Investors Pty Ltd raised its position in Danaher Co. (NYSE:DHR – Get Rating) by 20.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 100,149 shares of the conglomerate’s stock after acquiring an additional 16,955 shares during the period. IFM Investors Pty Ltd’s holdings in Danaher were worth $29,377,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. WealthBridge Capital Management LLC raised its holdings in shares of Danaher by 12.2% in the first quarter. WealthBridge Capital Management LLC now owns 1,818 shares of the conglomerate’s stock worth $533,000 after buying an additional 198 shares during the last quarter. City Holding Co. raised its holdings in shares of Danaher by 13.0% in the first quarter. City Holding Co. now owns 4,133 shares of the conglomerate’s stock worth $1,212,000 after buying an additional 475 shares during the last quarter. Atticus Wealth Management LLC raised its holdings in shares of Danaher by 4.7% in the first quarter. Atticus Wealth Management LLC now owns 1,026 shares of the conglomerate’s stock worth $301,000 after buying an additional 46 shares during the last quarter. Columbia Trust Co 01012016 raised its holdings in shares of Danaher by 29.8% in the first quarter. Columbia Trust Co 01012016 now owns 1,308 shares of the conglomerate’s stock worth $362,000 after buying an additional 300 shares during the last quarter. Finally, CRA Financial Services LLC raised its holdings in shares of Danaher by 23.8% in the first quarter. CRA Financial Services LLC now owns 1,039 shares of the conglomerate’s stock worth $305,000 after buying an additional 200 shares during the last quarter. 78.42% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Up 0.9 %

DHR stock opened at $291.47 on Monday. The firm has a market cap of $212.03 billion, a PE ratio of 34.33, a P/E/G ratio of 2.22 and a beta of 0.83. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.75. The firm’s fifty day moving average is $258.64 and its 200 day moving average is $268.12. Danaher Co. has a one year low of $233.71 and a one year high of $333.96.

Danaher (NYSE:DHR – Get Rating) last announced its earnings results on Thursday, July 21st. The conglomerate reported $2.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.35 by $0.41. Danaher had a net margin of 20.61% and a return on equity of 18.57%. The business had revenue of $7.75 billion for the quarter, compared to analyst estimates of $7.29 billion. During the same quarter last year, the business earned $2.46 earnings per share. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. On average, research analysts forecast that Danaher Co. will post 10.39 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, July 29th. Stockholders of record on Friday, June 24th were given a $0.25 dividend. The ex-dividend date was Thursday, June 23rd. This represents a $1.00 annualized dividend and a dividend yield of 0.34%. Danaher’s dividend payout ratio (DPR) is 11.78%.

Insider Activity

In other news, Director Walter G. Lohr sold 3,906 shares of Danaher stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $273.84, for a total value of $1,069,619.04. Following the sale, the director now owns 12,115 shares in the company, valued at $3,317,571.60. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, EVP Joakim Weidemanis sold 12,000 shares of the business’s stock in a transaction dated Monday, July 25th. The shares were sold at an average price of $271.13, for a total transaction of $3,253,560.00. Following the transaction, the executive vice president now directly owns 74,398 shares in the company, valued at $20,171,529.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Walter G. Lohr sold 3,906 shares of the business’s stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $273.84, for a total transaction of $1,069,619.04. Following the transaction, the director now owns 12,115 shares in the company, valued at $3,317,571.60. The disclosure for this sale can be found here. Company insiders own 11.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on DHR. Evercore ISI decreased their price target on shares of Danaher from $320.00 to $280.00 and set an “outperform” rating for the company in a report on Tuesday, July 5th. KeyCorp reduced their target price on shares of Danaher from $345.00 to $325.00 and set an “overweight” rating for the company in a report on Friday, July 22nd. StockNews.com raised shares of Danaher from a “buy” rating to a “strong-buy” rating in a report on Saturday. UBS Group raised their target price on shares of Danaher from $297.00 to $323.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Royal Bank of Canada raised their target price on shares of Danaher from $301.00 to $317.00 and gave the stock a “maintains” rating in a report on Friday, July 22nd. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $329.17.

Danaher Company Profile

(Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.